BIOMARIN PHARMACEUTICAL INC (BMRN) Operating Margin
- Operating margin · 12 months: Value 4.38%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 4.38% | Operating income / revenue. Period ending 2026-06-30. $149.26M ÷ $3.41B × 100 ≈ 4.38% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 149.26M USD | Operating Income (Loss) |
| Revenue | 3.41B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 987.64M USD | Research and Development Expense |
| Selling, general and administration | 1.37B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $149.26M | $3.41B | (m) | $987.64M | $1.37B | 4.38% |
| 2026-03-31 | $315.23M | $3.24B | (m) | $942.00M | $1.21B | 9.72% |
| 2025-12-31 | $409.48M | $3.22B | (m) | $921.93M | $1.15B | 12.71% |
| 2025-09-30 | $615.50M | $3.09B | (m) | $903.03M | $973.42M | 19.89% |
| 2025-06-30 | $776.08M | $3.06B | (m) | $678.45M | $958.48M | 25.33% |
| 2025-03-31 | $619.64M | $2.95B | (m) | $700.93M | $989.24M | 21.00% |
| 2024-12-31 | $484.21M | $2.85B | (m) | $747.18M | $1.01B | 16.97% |
| 2024-09-30 | $322.41M | $2.75B | (m) | $779.92M | $1.05B | 11.71% |
| 2024-06-30 | $239.04M | $2.59B | (m) | $786.34M | $1.01B | 9.24% |
| 2024-03-31 | $184.16M | $2.47B | (m) | $779.91M | $952.17M | 7.45% |
| 2023-12-31 | $158.10M | $2.42B | (m) | $746.77M | $937.29M | 6.54% |
| 2023-09-30 | $119.38M | $2.31B | (m) | $713.27M | $908.01M | 5.17% |
| 2023-06-30 | $91.30M | $2.23B | (m) | $679.79M | $900.89M | 4.09% |
| 2023-03-31 | $71.58M | $2.17B | (m) | $660.62M | $882.39M | 3.29% |
| 2022-12-31 | $149.56M | $2.10B | (m) | $649.61M | $854.01M | 7.14% |
| 2022-09-30 | $108.18M | $2.01B | (m) | $637.95M | $825.83M | 5.39% |
| 2022-06-30 | $57.38M | $1.91B | (m) | $637.99M | $792.35M | 3.00% |
| 2022-03-31 | $29.90M | $1.88B | (m) | $640.90M | $779.68M | 1.59% |
| 2021-12-31 | $-82.34M | $1.85B | (m) | $628.79M | $759.38M | -4.46% |
| 2021-09-30 | $-61.30M | $1.85B | (m) | $624.37M | $737.32M | -3.32% |
| 2021-06-30 | $-64.02M | $1.92B | (m) | $613.55M | $733.44M | -3.34% |
| 2021-03-31 | $-116.64M | $1.84B | (m) | $634.58M | $724.69M | -6.32% |
| 2020-12-31 | $-36.77M | $1.86B | (m) | $628.12M | $737.67M | -1.98% |
| 2020-09-30 | $-1.09M | $1.86B | (m) | $644.26M | $730.06M | -0.06% |
| 2020-06-30 | $58.86M | $1.85B | (m) | $670.17M | $720.72M | 3.19% |
| 2020-03-31 | $58.45M | $1.81B | (m) | $673.67M | $706.06M | 3.24% |
| 2019-12-31 | $-100.46M | $1.70B | (m) | $715.01M | $680.92M | -5.90% |
| 2019-09-30 | $-129.44M | $1.60B | (m) | $717.59M | $657.20M | -8.08% |
| 2019-06-30 | $-149.19M | $1.53B | (m) | $706.03M | $635.65M | -9.73% |
| 2019-03-31 | $-133.10M | $1.52B | (m) | $695.97M | $628.17M | -8.77% |
| 2018-12-31 | $-123.52M | $1.49B | (m) | $696.33M | $604.35M | -8.28% |
| 2018-09-30 | $-27.33M | $1.50B | (m) | $689.55M | $600.46M | -1.83% |
| 2018-06-30 | $-25.32M | $1.44B | (m) | $682.24M | $582.43M | -1.76% |
| 2018-03-31 | $-38.86M | $1.38B | (m) | $649.70M | $572.65M | -2.81% |
| 2017-12-31 | $-14.70M | $1.31B | (m) | $610.75M | $554.34M | -1.12% |
| 2017-09-30 | $-162.37M | $1.26B | (m) | $617.39M | $537.01M | -12.93% |
| 2017-06-30 | $-208.73M | $1.20B | (m) | $624.12M | $525.24M | -17.38% |
| 2017-03-31 | $-742.72M | $1.18B | (m) | $648.12M | $491.31M | -62.74% |
| 2016-12-31 | $-803.43M | $1.12B | (m) | $661.90M | $476.59M | -71.94% |
| 2016-09-30 | $-612.49M | $1.04B | (m) | $662.78M | $447.54M | -58.63% |
| 2016-06-30 | $-634.28M | $973.71M | (m) | $660.66M | $422.83M | -65.14% |
| 2016-03-31 | $-125.76M | $923.71M | (m) | $651.52M | $414.76M | -13.61% |
| 2015-12-31 | $-110.70M | $889.89M | (m) | $634.81M | $402.27M | -12.44% |
| 2015-09-30 | $-270.78M | $893.78M | (m) | $600.75M | $388.13M | -30.30% |
| 2015-06-30 | $-177.65M | $861.49M | (m) | $567.65M | $368.32M | -20.62% |
| 2015-03-31 | $-132.29M | $802.75M | (m) | $517.45M | $334.89M | -16.48% |
| 2014-12-31 | $-92.89M | $751.04M | (m) | $461.54M | $302.16M | -12.37% |
| 2014-09-30 | $-86.44M | $667.06M | (m) | $416.87M | $274.33M | -12.96% |
| 2014-06-30 | $-148.37M | $627.09M | (m) | $379.24M | $261.81M | -23.66% |
| 2014-03-31 | $-149.54M | $572.11M | (m) | $357.20M | $244.38M | -26.14% |
| 2013-12-31 | $-156.01M | $548.49M | (m) | $354.78M | $235.36M | -28.44% |
| 2013-09-30 | $-150.60M | $533.55M | (m) | $341.83M | $218.60M | -28.23% |
| 2013-06-30 | $-110.37M | $524.79M | (m) | $319.98M | $203.09M | -21.03% |
| 2013-03-31 | $-121.27M | $512.00M | (m) | $312.13M | $203.97M | -23.69% |
| 2012-12-31 | $-110.22M | $500.72M | (m) | $302.22M | $198.17M | -22.01% |
| 2012-09-30 | $-84.75M | $476.63M | (m) | $275.76M | $191.58M | -17.78% |
| 2012-06-30 | $-89.77M | $461.94M | (m) | $268.13M | $190.12M | -19.43% |
| 2012-03-31 | $-58.05M | $448.55M | (m) | $243.19M | $179.63M | -12.94% |
| 2011-12-31 | $-33.89M | $441.36M | (m) | $214.37M | $175.42M | -7.68% |
| 2011-09-30 | $-15.80M | $435.13M | (m) | $198.66M | $169.07M | -3.63% |
| 2011-06-30 | $-2.23M | $419.45M | (m) | $179.45M | $162.53M | -0.53% |
| 2011-03-31 | $48.00K | $400.77M | (m) | $162.23M | $158.76M | 0.01% |
| 2010-12-31 | $544.00K | $376.27M | (m) | $147.31M | $151.72M | 0.14% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $16.43M | $324.66M | (m) | $115.12M | $124.29M | 5.06% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $39.76M | $296.49M | (m) | $93.29M | $106.57M | 13.41% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |